ChartMill assigns a Buy % Consensus number of 80% to FWBI. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-03-25 | HC Wainwright & Co. | Reiterate | Neutral |
| 2024-03-15 | Roth MKM | Maintains | Buy -> Buy |
| 2024-01-03 | Roth MKM | Maintains | Buy -> Buy |
| 2023-09-19 | Roth MKM | Reiterate | Buy -> Buy |
| 2023-07-14 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2023-06-29 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-06-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-04-26 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-04-05 | HC Wainwright & Co. | Maintains | Buy |
| 2023-03-09 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-02-03 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-01-31 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-01-26 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-12-02 | HC Wainwright & Co. | Maintains | Buy |
| 2022-05-26 | Roth Capital | Maintains | Buy |
| 2021-12-07 | Maxim Group | Downgrade | Buy -> Hold |
8 analysts have analysed FWBI and the average price target is 36.72 USD. This implies a price increase of 1140.54% is expected in the next year compared to the current price of 2.96.
The consensus rating for FIRST WAVE BIOPHARMA (FWBI) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.
The number of analysts covering FIRST WAVE BIOPHARMA (FWBI) is 8.